<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Crit Care</journal-id><journal-title>Critical Care</journal-title><issn pub-type="ppub">1364-8535</issn><issn pub-type="epub">1466-609X</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">15987392</article-id><article-id pub-id-type="pmc">1175881</article-id><article-id pub-id-type="publisher-id">cc3497</article-id><article-id pub-id-type="doi">10.1186/cc3497</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Tezosentan-induced attenuation of lung injury in endotoxemic sheep is associated with reduced activation of protein kinase C</article-title></title-group><contrib-group><contrib id="A1" contrib-type="author"><name><surname>Kuklin</surname><given-names>Vladimir</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>Vladimir.Kuklin@unn.no</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Kirov</surname><given-names>Mikhail</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>kirm@arh.ru</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Sovershaev</surname><given-names>Mikhail</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>Mikhail.Sovershaev@fagmed.uit.no</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Andreasen</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>Thomas.V.Andreasen</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Ingebretsen</surname><given-names>Ole C</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>Ole.Christian.Ingebretsen@unn.no</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Ytrehus</surname><given-names>Kirsti</given-names></name><xref ref-type="aff" rid="I5">5</xref><email>kirstiy@fagmed.uit.no</email></contrib><contrib id="A7" corresp="yes" contrib-type="author"><name><surname>Bjertnaes</surname><given-names>Lars</given-names></name><xref ref-type="aff" rid="I6">6</xref><email>lars.bjertnaes@unn.no</email></contrib></contrib-group><aff id="I1"><label>1</label>Research Fellow, Department of Anesthesiology, Faculty of Medicine, University of Tromsø, Norway</aff><aff id="I2"><label>2</label>Research Fellow, Department of Physiology, Faculty of Medicine, University of Tromsø, Norway</aff><aff id="I3"><label>3</label>Departmental engineer, Department of Physiology, Faculty of Medicine, University of Tromsø, Norway</aff><aff id="I4"><label>4</label>Professor, Department of Clinical Chemistry, University Hospital of Tromsø, Norway</aff><aff id="I5"><label>5</label>Professor, Department of Physiology, Faculty of Medicine, University of Tromsø, Norway</aff><aff id="I6"><label>6</label>Professor, Chairman of the Department of Anesthesiology, Faculty of Medicine, University of Tromsø, Norway</aff><pub-date pub-type="ppub"><year>2005</year></pub-date><pub-date pub-type="epub"><day>14</day><month>3</month><year>2005</year></pub-date><volume>9</volume><issue>3</issue><fpage>R211</fpage><lpage>R217</lpage><ext-link ext-link-type="uri" xlink:href="http://ccforum.com/content/9/3/R211"></ext-link><history><date date-type="received"><day>24</day><month>11</month><year>2004</year></date><date date-type="rev-request"><day>9</day><month>1</month><year>2005</year></date><date date-type="rev-recd"><day>27</day><month>1</month><year>2005</year></date><date date-type="accepted"><day>16</day><month>2</month><year>2005</year></date></history><copyright-statement>Copyright © 2005 Kuklin et al.; licensee BioMed Central Ltd.</copyright-statement><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"></ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license><abstract><sec><title><offsets xml_i="4339" xml_f="4351" txt_i="11" txt_f="23">Introduction</offsets></title><p><offsets xml_i="4362" xml_f="4370" txt_i="24" txt_f="32">Studies </offsets><italic><offsets xml_i="4378" xml_f="4387" txt_i="32" txt_f="41">in vitro </offsets></italic><offsets xml_i="4396" xml_f="5028" txt_i="41" txt_f="673">reveal that endothelin-1 (ET-1) activates the α isoform of protein kinase C (PKC-α) in cultures of endothelial cells, thereby deranging cellular integrity. Sepsis and endotoxemia are associated with increased plasma concentrations of ET-1 that induce acute lung injury (ALI). We recently reported that non-selective ET-1 receptor blockade attenuates ALI in sheep by reducing the endotoxin-induced increase in extravascular lung water index (EVLWI). The aim of this study was to find out whether this attenuation is associated with reduced translocation of PKC-α from the cytosolic to the membrane fraction of lung tissue homogenate.</offsets></p></sec><sec sec-type="methods"><title><offsets xml_i="5069" xml_f="5076" txt_i="675" txt_f="682">Methods</offsets></title><p><offsets xml_i="5087" xml_f="5708" txt_i="683" txt_f="1304">Seventeen awake, instrumented sheep were randomly assigned to a sham-operated group (n = 3), a lipopolysaccharide (LPS) group (n = 7) receiving an intravenous infusion of Escherichia coli 15 ng/kg per min for 24 hours, and a tezosentan group (n = 7) subjected to LPS and, from 4 hours, an intravenous injection of tezosentan 3 mg/kg followed by infusion at 1 mg/kg per hour for the reminder of the experiment. Pulmonary micro-occlusion pressure (Pmo), EVLWI, plasma concentrations of ET-1, tumor necrosis factor-a (TNF-a), and interleukin-8 (IL-8) were determined every 4 hours. Western blotting was used to assess PKC-α.</offsets></p></sec><sec><title><offsets xml_i="5730" xml_f="5737" txt_i="1306" txt_f="1313">Results</offsets></title><p><offsets xml_i="5748" xml_f="6531" txt_i="1314" txt_f="2097">In non-treated sheep a positive correlation was found between the plasma concentration of ET-1 and Pmo in the late phase of endotoxemia (12 to 24 hours). A positive correlation was also noticed between Pmo and EVLWI in the LPS and the LPS plus tezosentan groups, although the latter was significantly reduced in comparison with LPS alone. In both endotoxemic groups, plasma concentrations of ET-1, TNF-α, and IL-8 increased. In the LPS group, the cytosolic fraction of PKC-α decreased by 75% whereas the membrane fraction increased by 40% in comparison with the sham-operated animals. Tezosentan completely prevented the changes in PKC-α in both the cytosolic and the membrane fractions, concomitantly causing a further increase in the plasma concentrations of ET-1, TNF-α, and IL-8.</offsets></p></sec><sec><title><offsets xml_i="6553" xml_f="6563" txt_i="2099" txt_f="2109">Conclusion</offsets></title><p><offsets xml_i="6574" xml_f="6752" txt_i="2110" txt_f="2288">In endotoxemic sheep, ET-1 receptor blockade alleviates lung injury as assessed by a decrease in EVLWI paralleled by a reduction in Pmo and the prevention of activation of PKC-α.</offsets></p></sec></abstract></article-meta><notes><p>See related commentary <ext-link ext-link-type="uri" xlink:href="http://ccforum.com/content/9/3/245"></ext-link></p></notes></front><body><sec><title><offsets xml_i="6948" xml_f="6960" txt_i="2297" txt_f="2309">Introduction</offsets></title><p><offsets xml_i="6971" xml_f="7068" txt_i="2310" txt_f="2407">Endothelin-1 (ET-1) has been identified as the most potent vasoconstrictor peptide known so far [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="7099" xml_f="7100" txt_i="2407" txt_f="2408">1</offsets></xref><offsets xml_i="7107" xml_f="7108" txt_i="2408" txt_f="2409">,</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="7139" xml_f="7140" txt_i="2409" txt_f="2410">2</offsets></xref><offsets xml_i="7147" xml_f="7225" txt_i="2410" txt_f="2488">]. Locally produced ET-1 acts on three types of G-protein-coupled receptor: ET</offsets><sub><offsets xml_i="7230" xml_f="7231" txt_i="2488" txt_f="2489">A</offsets></sub><offsets xml_i="7237" xml_f="7241" txt_i="2489" txt_f="2493">, ET</offsets><sub><offsets xml_i="7246" xml_f="7248" txt_i="2493" txt_f="2495">B1</offsets></sub><offsets xml_i="7254" xml_f="7262" txt_i="2495" txt_f="2503">, and ET</offsets><sub><offsets xml_i="7267" xml_f="7270" txt_i="2503" txt_f="2506">B2 </offsets></sub><offsets xml_i="7276" xml_f="7277" txt_i="2506" txt_f="2507">[</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="7308" xml_f="7309" txt_i="2507" txt_f="2508">3</offsets></xref><offsets xml_i="7316" xml_f="7325" txt_i="2508" txt_f="2517">]. The ET</offsets><sub><offsets xml_i="7330" xml_f="7332" txt_i="2517" txt_f="2519">A </offsets></sub><offsets xml_i="7338" xml_f="7344" txt_i="2519" txt_f="2525">and ET</offsets><sub><offsets xml_i="7349" xml_f="7352" txt_i="2525" txt_f="2528">B2 </offsets></sub><offsets xml_i="7358" xml_f="7425" txt_i="2528" txt_f="2595">receptors are expressed in vascular smooth muscle cells, whereas ET</offsets><sub><offsets xml_i="7430" xml_f="7433" txt_i="2595" txt_f="2598">B1 </offsets></sub><offsets xml_i="7439" xml_f="7500" txt_i="2598" txt_f="2659">is localized mainly in the endothelium. Binding of ET-1 to ET</offsets><sub><offsets xml_i="7505" xml_f="7507" txt_i="2659" txt_f="2661">A </offsets></sub><offsets xml_i="7513" xml_f="7519" txt_i="2661" txt_f="2667">and ET</offsets><sub><offsets xml_i="7524" xml_f="7527" txt_i="2667" txt_f="2670">B2 </offsets></sub><offsets xml_i="7533" xml_f="7575" txt_i="2670" txt_f="2712">leads to vascular constriction, whereas ET</offsets><sub><offsets xml_i="7580" xml_f="7583" txt_i="2712" txt_f="2715">B1 </offsets></sub><offsets xml_i="7589" xml_f="7652" txt_i="2715" txt_f="2778">induces relaxation by releasing nitric oxide and prostacyclin [</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="7683" xml_f="7684" txt_i="2778" txt_f="2779">4</offsets></xref><offsets xml_i="7691" xml_f="7755" txt_i="2779" txt_f="2843">]. In the lowest concentration range, ET-1 mainly acts on the ET</offsets><sub><offsets xml_i="7760" xml_f="7763" txt_i="2843" txt_f="2846">B1 </offsets></sub><offsets xml_i="7769" xml_f="7779" txt_i="2846" txt_f="2856">receptor [</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="7810" xml_f="7811" txt_i="2856" txt_f="2857">5</offsets></xref><offsets xml_i="7818" xml_f="7820" txt_i="2857" txt_f="2859">].</offsets></p><p><offsets xml_i="7827" xml_f="8009" txt_i="2860" txt_f="3042">In sepsis, endotoxin and other microbial products that are released into the bloodstream trigger endothelial cells to the enhanced generation of ET-1 causing local vasoconstriction [</offsets><xref ref-type="bibr" rid="B6"><offsets xml_i="8040" xml_f="8041" txt_i="3042" txt_f="3043">6</offsets></xref><offsets xml_i="8048" xml_f="8049" txt_i="3043" txt_f="3044">-</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="8080" xml_f="8081" txt_i="3044" txt_f="3045">9</offsets></xref><offsets xml_i="8088" xml_f="8169" txt_i="3045" txt_f="3126">]. The effect of ET-1 is most prominent in the pulmonary circulation where the ET</offsets><sub><offsets xml_i="8174" xml_f="8176" txt_i="3126" txt_f="3128">A </offsets></sub><offsets xml_i="8182" xml_f="8188" txt_i="3128" txt_f="3134">and ET</offsets><sub><offsets xml_i="8193" xml_f="8195" txt_i="3134" txt_f="3136">B </offsets></sub><offsets xml_i="8201" xml_f="8235" txt_i="3136" txt_f="3170">receptors are widely distributed [</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="8267" xml_f="8269" txt_i="3170" txt_f="3172">10</offsets></xref><offsets xml_i="8276" xml_f="8277" txt_i="3172" txt_f="3173">,</offsets><xref ref-type="bibr" rid="B11"><offsets xml_i="8309" xml_f="8311" txt_i="3173" txt_f="3175">11</offsets></xref><offsets xml_i="8318" xml_f="8452" txt_i="3175" txt_f="3309">]. Previous investigators have noticed that intravenously infused ET-1 results in increased pulmonary artery pressure and lung edema [</offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="8484" xml_f="8486" txt_i="3309" txt_f="3311">12</offsets></xref><offsets xml_i="8493" xml_f="8494" txt_i="3311" txt_f="3312">,</offsets><xref ref-type="bibr" rid="B13"><offsets xml_i="8526" xml_f="8528" txt_i="3312" txt_f="3314">13</offsets></xref><offsets xml_i="8535" xml_f="8712" txt_i="3314" txt_f="3491">]. Moreover, in isolated rat lungs in which the vasculature has been paralyzed, ET-1 enhances microvascular permeability, but the mechanisms involved have not yet been settled [</offsets><xref ref-type="bibr" rid="B14"><offsets xml_i="8744" xml_f="8746" txt_i="3491" txt_f="3493">14</offsets></xref><offsets xml_i="8753" xml_f="8755" txt_i="3493" txt_f="3495">].</offsets></p><p><offsets xml_i="8762" xml_f="8770" txt_i="3496" txt_f="3504">Studies </offsets><italic><offsets xml_i="8778" xml_f="8787" txt_i="3504" txt_f="3513">in vitro </offsets></italic><offsets xml_i="8796" xml_f="8903" txt_i="3513" txt_f="3620">have shown that the binding of ET-1 to its receptor might induce the activation of protein kinase C (PKC) [</offsets><xref ref-type="bibr" rid="B15"><offsets xml_i="8935" xml_f="8937" txt_i="3620" txt_f="3622">15</offsets></xref><offsets xml_i="8944" xml_f="8945" txt_i="3622" txt_f="3623">,</offsets><xref ref-type="bibr" rid="B16"><offsets xml_i="8977" xml_f="8979" txt_i="3623" txt_f="3625">16</offsets></xref><offsets xml_i="8986" xml_f="9184" txt_i="3625" txt_f="3823">]. Activation of the α isoform of PKC (PKC-α) might cause disturbances in the shape of the cells as well as of the intercellular junctions. The latter changes might promote acute lung injury (ALI) [</offsets><xref ref-type="bibr" rid="B17"><offsets xml_i="9216" xml_f="9218" txt_i="3823" txt_f="3825">17</offsets></xref><offsets xml_i="9225" xml_f="9226" txt_i="3825" txt_f="3826">-</offsets><xref ref-type="bibr" rid="B19"><offsets xml_i="9258" xml_f="9260" txt_i="3826" txt_f="3828">19</offsets></xref><offsets xml_i="9267" xml_f="9324" txt_i="3828" txt_f="3885">]. However, we are unable to determine whether any study </offsets><italic><offsets xml_i="9332" xml_f="9340" txt_i="3885" txt_f="3893">in vivo </offsets></italic><offsets xml_i="9349" xml_f="9412" txt_i="3893" txt_f="3956">has tested whether PKC-α is activated in endotoxin-induced ALI.</offsets></p><p><offsets xml_i="9419" xml_f="9509" txt_i="3957" txt_f="4047">In sheep subjected to continuous infusion of endotoxin, we recently found that the dual ET</offsets><sub><offsets xml_i="9514" xml_f="9516" txt_i="4047" txt_f="4049">A </offsets></sub><offsets xml_i="9522" xml_f="9528" txt_i="4049" txt_f="4055">and ET</offsets><sub><offsets xml_i="9533" xml_f="9535" txt_i="4055" txt_f="4057">B </offsets></sub><offsets xml_i="9541" xml_f="9737" txt_i="4057" txt_f="4253">receptor blocker tezosentan precludes ALI as evaluated by improved gas exchange and a partial reversal of the increases in pulmonary vascular pressures and extravascular lung water index (EVLWI) [</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="9768" xml_f="9769" txt_i="4253" txt_f="4254">9</offsets></xref><offsets xml_i="9776" xml_f="10109" txt_i="4254" txt_f="4587">]. However, the mechanisms involved in the tezosentan-induced reduction of EVLWI still remain obscure. We speculate whether non-selective blockade of ET-1 receptor by tezosentan alleviates ALI by dampening the activation of PKC-α and modulating inflammatory mediators such as tumor necrosis factor-α (TNF-α) and interleukin-8 (IL-8).</offsets></p><p><offsets xml_i="10116" xml_f="10611" txt_i="4588" txt_f="5083">The aim of the present study was twofold: first, to investigate in sheep subjected to endotoxin-induced lung injury whether a relationship exists between the plasma concentration of ET-1 and characteristics of ALI such as the increases in lung microvascular pressure and extravascular lung water content, with or without tezosentan; and second, to assess the effects of tezosentan on the activation of PKC-α in lung tissue in parallel with changes in the plasma concentrations of TNF-α and IL-8.</offsets></p></sec><sec sec-type="methods"><title><offsets xml_i="10652" xml_f="10659" txt_i="5085" txt_f="5092">Methods</offsets></title><p><offsets xml_i="10670" xml_f="10770" txt_i="5093" txt_f="5193">The present investigation is based partly on data from a previously published study from our group [</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="10801" xml_f="10802" txt_i="5193" txt_f="5194">9</offsets></xref><offsets xml_i="10809" xml_f="10872" txt_i="5194" txt_f="5257">] that was approved by the Norwegian Experimental Animal Board.</offsets></p><p><offsets xml_i="10879" xml_f="11201" txt_i="5258" txt_f="5580">In brief, 17 yearling sheep were instrumented with a pulmonary artery thermal dilution catheter introduced via an introducer in the left external jugular vein, a thermo-dye dilution catheter introduced via an introducer in the ipsilateral common carotid artery, and a catheter in the left atrium, as described previously [</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="11232" xml_f="11233" txt_i="5580" txt_f="5581">9</offsets></xref><offsets xml_i="11240" xml_f="11242" txt_i="5581" txt_f="5583">].</offsets></p><sec><title><offsets xml_i="11258" xml_f="11279" txt_i="5584" txt_f="5605">Experimental protocol</offsets></title><p><offsets xml_i="11290" xml_f="11351" txt_i="5606" txt_f="5667">The animals were randomly assigned to a sham-operated group (</offsets><italic><offsets xml_i="11359" xml_f="11361" txt_i="5667" txt_f="5669">n </offsets></italic><offsets xml_i="11370" xml_f="11385" txt_i="5669" txt_f="5684">= 3), a group (</offsets><italic><offsets xml_i="11393" xml_f="11395" txt_i="5684" txt_f="5686">n </offsets></italic><offsets xml_i="11404" xml_f="11446" txt_i="5686" txt_f="5728">= 7) receiving an intravenous infusion of </offsets><italic><offsets xml_i="11454" xml_f="11471" txt_i="5728" txt_f="5745">Escherichia coli </offsets></italic><offsets xml_i="11480" xml_f="11561" txt_i="5745" txt_f="5826">lipopolysaccharide (LPS) 15 ng/kg per min for 24 hours (LPS group), and a group (</offsets><italic><offsets xml_i="11569" xml_f="11571" txt_i="5826" txt_f="5828">n </offsets></italic><offsets xml_i="11580" xml_f="11844" txt_i="5828" txt_f="6092">= 7) subjected to LPS and, from 4 hours, an intravenous injection of tezosentan 3 mg/kg followed by infusion at 1 mg/kg per hour for the reminder of the 24-hour experiment (LPS plus tezosentan group). During the experiment, sheep had free access to food and water.</offsets></p><p><offsets xml_i="11851" xml_f="12057" txt_i="6093" txt_f="6299">EVLWI was assessed by the thermal-dye dilution method (Cold Z-021; Pulsion Medical Systems, Munich, Germany). Pulmonary micro-occlusion pressure (Pmo) was determined every 4 hours, as described previously [</offsets><xref ref-type="bibr" rid="B20"><offsets xml_i="12089" xml_f="12091" txt_i="6299" txt_f="6301">20</offsets></xref><offsets xml_i="12098" xml_f="12426" txt_i="6301" txt_f="6629">]. In brief, Pmo was determined by advancing the Swan-Ganz catheter into the occlusion position in a distal pulmonary artery with the balloon deflated. The criteria for attainment of the micro-occlusion position included: first, easy retrograde aspiration of blood from the catheter; second, a pH, partial pressure of oxygen (PO</offsets><sub><offsets xml_i="12431" xml_f="12432" txt_i="6629" txt_f="6630">2</offsets></sub><offsets xml_i="12438" xml_f="12463" txt_i="6630" txt_f="6655">) and carbon dioxide (PCO</offsets><sub><offsets xml_i="12468" xml_f="12469" txt_i="6655" txt_f="6656">2</offsets></sub><offsets xml_i="12475" xml_f="12643" txt_i="6656" txt_f="6824">) of aspirated blood consistent with occlusion position, that is, partial pressure of oxygen in occlusion position higher than arterial partial pressure of oxygen (PmoO</offsets><sub><offsets xml_i="12648" xml_f="12650" txt_i="6824" txt_f="6826">2 </offsets></sub><offsets xml_i="12656" xml_f="12664" txt_i="6826" txt_f="6831">&gt; PaO</offsets><sub><offsets xml_i="12669" xml_f="12670" txt_i="6831" txt_f="6832">2</offsets></sub><offsets xml_i="12676" xml_f="12801" txt_i="6832" txt_f="6957">) and partial pressure of carbon dioxide in occlusion position higher than arterial partial pressure of carbon dioxide (PmoCO</offsets><sub><offsets xml_i="12806" xml_f="12808" txt_i="6957" txt_f="6959">2 </offsets></sub><offsets xml_i="12814" xml_f="12823" txt_i="6959" txt_f="6965">&lt; PaCO</offsets><sub><offsets xml_i="12828" xml_f="12829" txt_i="6965" txt_f="6966">2</offsets></sub><offsets xml_i="12835" xml_f="13294" txt_i="6966" txt_f="7425">); third, micro-occlusion pressure greater than proximal occlusion pressure; and fourth, micro-occlusion pressure greater than left atrial pressure, with true zero confirmed by connecting the left atrial catheter and the Swan-Ganz catheter sequentially to the same fixed transducer. Blood for biochemical analysis was sampled at 0, 4, 12, and 24 hours. After the sheep had been killed, lung samples were taken and kept in liquid nitrogen for further analyses.</offsets></p></sec><sec><title><offsets xml_i="13316" xml_f="13332" txt_i="7427" txt_f="7443">Western blotting</offsets></title><p><offsets xml_i="13343" xml_f="13845" txt_i="7444" txt_f="7946">The activation of PKC-α was assessed by translocation of kinase from cytosolic and/or membrane fractions of lung tissue extracts. In brief, lung tissue samples were homogenized (Polytron homogenizer, blade rotation speed 5,000 r.p.m.) in 1 ml of ice-cold extraction buffer consisting of (in mmol/l): 250 sucrose, 1 EDTA, 1 EGTA, 20 Tris-HCl pH 7.5, 10 2-mercaptoethanol, 20 dithiothreitol and 1 tablet of Complete™ EDTA-free protease inhibitor cocktail per 10 ml. Crude extracts were centrifuged at 200</offsets><italic><offsets xml_i="13853" xml_f="13855" txt_i="7946" txt_f="7948">g </offsets></italic><offsets xml_i="13864" xml_f="13901" txt_i="7948" txt_f="7985">to remove debris, followed by 100,000</offsets><italic><offsets xml_i="13909" xml_f="13911" txt_i="7985" txt_f="7987">g </offsets></italic><offsets xml_i="13920" xml_f="14121" txt_i="7987" txt_f="8188">for 60 min at 4°C. The supernatant represented the cytosolic fraction. The pellet was resuspended by sonication in 200 ml of a similar buffer supplemented with 1% Triton X-100 and centrifuged at 25,000</offsets><italic><offsets xml_i="14129" xml_f="14131" txt_i="8188" txt_f="8190">g </offsets></italic><offsets xml_i="14140" xml_f="14915" txt_i="8190" txt_f="8965">for 15 min at 4°C. The supernatant was collected as the Triton X-100-soluble membrane fraction. For SDS-PAGE, 10% polyacrylamide gels were loaded with 10 mg of protein per lane. After the end of electrophoresis, proteins were electroblotted to nitrocellulose membranes. Membranes were probed overnight with anti-PKC-α primary antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA) at 4°C and for 1 hour with sheep anti-rabbit horseradish peroxidase-conjugated secondary antibodies (Zymed, San Francisco, CA, USA) at 22°C. Blots were incubated with ChemiLucent detection kit (Chemicon, Temecula, CA, USA). Immunopositive bands of PKC-α were detected with a Kodak Image Station 1000 (Kodak, Rochester, NY, USA) and densitometry readings were taken for statistical analysis.</offsets></p></sec><sec><title><offsets xml_i="14937" xml_f="14961" txt_i="8967" txt_f="8991">Biochemical measurements</offsets></title><p><offsets xml_i="14972" xml_f="15241" txt_i="8992" txt_f="9257">The ET-1 plasma levels were measured by chemiluminescent enzyme immunoassay (QuantiGlo QET00; R&amp;D Systems, Minneapolis, MN, USA). Plasma levels of TNF-α and of IL-8 were determined with an Immulite instrument (Diagnostic Products Corporation, Los Angeles, CA, USA).</offsets></p></sec><sec><title><offsets xml_i="15263" xml_f="15283" txt_i="9259" txt_f="9279">Statistical analysis</offsets></title><p><offsets xml_i="15294" xml_f="15615" txt_i="9280" txt_f="9601">Data were checked for normal distribution by the Kolmogorov–Smirnov test. The relationship between ET-1, Pmo, and EVLWI was evaluated by regression analysis with the Pearson correlation coefficient. Equality of regression lines between the LPS and the LPS plus tezosentan groups was tested by single multiple regression [</offsets><xref ref-type="bibr" rid="B21"><offsets xml_i="15647" xml_f="15649" txt_i="9601" txt_f="9603">21</offsets></xref><offsets xml_i="15656" xml_f="15895" txt_i="9603" txt_f="9842">]. The detected relative amounts of PKC-α in the groups and tissue fractions were compared by one-way analysis of variance. Plasma concentrations of ET-1, TNF-α, and IL-8 were analyzed by analysis of variance for repeated measurements. If </offsets><italic><offsets xml_i="15903" xml_f="15905" txt_i="9842" txt_f="9844">F </offsets></italic><offsets xml_i="15914" xml_f="15973" txt_i="9844" txt_f="9903">was statistically significant, Scheffe's test was used for </offsets><italic><offsets xml_i="15981" xml_f="15990" txt_i="9903" txt_f="9912">post hoc </offsets></italic><offsets xml_i="15999" xml_f="16140" txt_i="9912" txt_f="10053">intergroup analysis. To evaluate differences within groups towards the baseline value (time 0 hours), we used test of contrasts. We regarded </offsets><italic><offsets xml_i="16148" xml_f="16150" txt_i="10053" txt_f="10055">P </offsets></italic><offsets xml_i="16159" xml_f="16198" txt_i="10055" txt_f="10091">&lt; 0.05 as statistically significant.</offsets></p></sec></sec><sec><title><offsets xml_i="16226" xml_f="16233" txt_i="10094" txt_f="10101">Results</offsets></title><p><offsets xml_i="16244" xml_f="16480" txt_i="10102" txt_f="10338">In sham-operated sheep, all variables remained unchanged throughout the 24-hour experiments. During the first 12 hours we found no significant correlation between the plasma concentration of ET-1 and Pmo in sheep subjected to LPS (Fig. </offsets><xref ref-type="fig" rid="F1"><offsets xml_i="16510" xml_f="16512" txt_i="10338" txt_f="10340">1a</offsets></xref><offsets xml_i="16519" xml_f="16608" txt_i="10340" txt_f="10429">). In contrast, we found a positive correlation between these variables beyond 12 hours (</offsets><italic><offsets xml_i="16616" xml_f="16618" txt_i="10429" txt_f="10431">P </offsets></italic><offsets xml_i="16627" xml_f="16643" txt_i="10431" txt_f="10444">&lt; 0.01; Fig. </offsets><xref ref-type="fig" rid="F1"><offsets xml_i="16673" xml_f="16675" txt_i="10444" txt_f="10446">1b</offsets></xref><offsets xml_i="16682" xml_f="16810" txt_i="10446" txt_f="10574">). A positive correlation also existed between Pmo and EVLWI in the LPS and the LPS plus tezosentan groups, as depicted in Fig. </offsets><xref ref-type="fig" rid="F2"><offsets xml_i="16840" xml_f="16841" txt_i="10574" txt_f="10575">2</offsets></xref><offsets xml_i="16848" xml_f="16936" txt_i="10575" txt_f="10663">. However, tezosentan reduced the slope of the regression line compared with LPS alone (</offsets><italic><offsets xml_i="16944" xml_f="16946" txt_i="10663" txt_f="10665">P </offsets></italic><offsets xml_i="16955" xml_f="16971" txt_i="10665" txt_f="10678">&lt; 0.05; Fig. </offsets><xref ref-type="fig" rid="F2"><offsets xml_i="17001" xml_f="17002" txt_i="10678" txt_f="10679">2</offsets></xref><offsets xml_i="17009" xml_f="17011" txt_i="10679" txt_f="10681">).</offsets></p><p><offsets xml_i="17018" xml_f="17035" txt_i="10682" txt_f="10699">As shown in Fig. </offsets><xref ref-type="fig" rid="F3"><offsets xml_i="17065" xml_f="17066" txt_i="10699" txt_f="10700">3</offsets></xref><offsets xml_i="17073" xml_f="17241" txt_i="10700" txt_f="10868">, extracts of lung tissue from sheep exposed to LPS displayed a 75% reduction of the cytosolic fraction of PKC-α in comparison with samples from sham-operated animals (</offsets><italic><offsets xml_i="17249" xml_f="17251" txt_i="10868" txt_f="10870">P </offsets></italic><offsets xml_i="17260" xml_f="17509" txt_i="10870" txt_f="11116">&lt; 0.05). The membrane fraction of PKC-α simultaneously increased by 40% in the LPS group compared with sham-operated sheep. Administration of tezosentan completely prevented the translocation of PKC-α from the cytosolic to the membrane fractions.</offsets></p><p><offsets xml_i="17516" xml_f="17523" txt_i="11117" txt_f="11124">Figure </offsets><xref ref-type="fig" rid="F4"><offsets xml_i="17553" xml_f="17554" txt_i="11124" txt_f="11125">4</offsets></xref><offsets xml_i="17561" xml_f="17757" txt_i="11125" txt_f="11321"> shows that after 4 hours of exposure to LPS, in parallel with the rise in ET-1, the plasma concentrations of TNF-α and IL-8 increased compared with intragroup baseline and sham-operated animals (</offsets><italic><offsets xml_i="17765" xml_f="17767" txt_i="11321" txt_f="11323">P </offsets></italic><offsets xml_i="17776" xml_f="17956" txt_i="11323" txt_f="11500">&lt; 0.05). Notably, on cessation of the experiment, plasma concentrations of ET-1, TNF-α, and IL-8 were significantly higher in the LPS plus tezosentan group than with LPS alone (</offsets><italic><offsets xml_i="17964" xml_f="17966" txt_i="11500" txt_f="11502">P </offsets></italic><offsets xml_i="17975" xml_f="17986" txt_i="11502" txt_f="11510">&lt; 0.05).</offsets></p></sec><sec><title><offsets xml_i="18008" xml_f="18018" txt_i="11512" txt_f="11522">Discussion</offsets></title><p><offsets xml_i="18029" xml_f="18718" txt_i="11523" txt_f="12212">The present study shows that during the late phase of endotoxemia in sheep (12 to 24 hours), the plasma concentration of ET-1 is significantly correlated with the microvascular pressure, whereas no such correlation was found during the early phase. Moreover, we observed a significant and positive correlation throughout the experiment between microvascular pressure and EVLWI in both endotoxemic groups. Interestingly, the regression line had a significantly lower slope in animals receiving tezosentan. To our knowledge, this is the first study demonstrating that blockade of ET-1 receptors precludes endotoxin-induced changes in PKC-α in cytosolic and membrane fractions of lung tissue.</offsets></p><p><offsets xml_i="18725" xml_f="18817" txt_i="12213" txt_f="12305">Pulmonary microvascular pressure and permeability are important determinants of lung edema [</offsets><xref ref-type="bibr" rid="B22"><offsets xml_i="18849" xml_f="18851" txt_i="12305" txt_f="12307">22</offsets></xref><offsets xml_i="18858" xml_f="19029" txt_i="12307" txt_f="12478">]. As reported previously by our group and others, increases in EVLWI in animals exposed to infusion of LPS are associated with enhanced pulmonary microvascular pressure [</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="19060" xml_f="19061" txt_i="12478" txt_f="12479">9</offsets></xref><offsets xml_i="19068" xml_f="19069" txt_i="12479" txt_f="12480">,</offsets><xref ref-type="bibr" rid="B23"><offsets xml_i="19101" xml_f="19103" txt_i="12480" txt_f="12482">23</offsets></xref><offsets xml_i="19110" xml_f="19111" txt_i="12482" txt_f="12483">,</offsets><xref ref-type="bibr" rid="B24"><offsets xml_i="19143" xml_f="19145" txt_i="12483" txt_f="12485">24</offsets></xref><offsets xml_i="19152" xml_f="19589" txt_i="12485" txt_f="12922">]. However, none of these investigators have focused on the relationship between the plasma concentration of ET-1 and the pulmonary microvascular pressure. There is therefore no general agreement about where in the course of illness, or how, ET-1 exerts its action. One previous report suggests that ET-1 contributes directly to the severity of ALI by increasing the pulmonary microvascular pressure from the first hours of endotoxemia [</offsets><xref ref-type="bibr" rid="B25"><offsets xml_i="19621" xml_f="19623" txt_i="12922" txt_f="12924">25</offsets></xref><offsets xml_i="19630" xml_f="19885" txt_i="12924" txt_f="13179">]. However, at variance with these results, we found that a fairly strong correlation between the plasma concentration of ET-1 and Pmo exists only in the late phase of endotoxemia. This is also in accordance with investigators who argue that thromboxane A</offsets><sub><offsets xml_i="19890" xml_f="19892" txt_i="13179" txt_f="13181">2 </offsets></sub><offsets xml_i="19898" xml_f="20052" txt_i="13181" txt_f="13335">is the dominating mediator of vasoconstriction during the first hours of endotoxemia, whereas ET-1 is responsible for vasoconstriction in the late phase [</offsets><xref ref-type="bibr" rid="B26"><offsets xml_i="20084" xml_f="20086" txt_i="13335" txt_f="13337">26</offsets></xref><offsets xml_i="20093" xml_f="20094" txt_i="13337" txt_f="13338">-</offsets><xref ref-type="bibr" rid="B29"><offsets xml_i="20126" xml_f="20128" txt_i="13338" txt_f="13340">29</offsets></xref><offsets xml_i="20135" xml_f="20137" txt_i="13340" txt_f="13342">].</offsets></p><p><offsets xml_i="20144" xml_f="20353" txt_i="13343" txt_f="13552">The significantly positive correlation between Pmo and EVLWI in endotoxemia, and the decrease in the relationship after treatment with tezosentan, agrees fully with a recent investigation in endotoxemic pigs [</offsets><xref ref-type="bibr" rid="B30"><offsets xml_i="20385" xml_f="20387" txt_i="13552" txt_f="13554">30</offsets></xref><offsets xml_i="20394" xml_f="20911" txt_i="13554" txt_f="14071">]. However, the beneficial effects of ET-1 blockade cannot be explained solely by attenuation of the endotoxin-induced increase in pulmonary artery pressure. The declining slope of the regression line between Pmo and EVLWI in tezosentan-treated animals indicates that additional factors affecting lung fluid filtration might be active. A few years ago, investigators found that ET-1 increases fluid filtration in isolated blood-perfused rat lungs pretreated with papaverine to deprive the lungs of any vascular tone [</offsets><xref ref-type="bibr" rid="B14"><offsets xml_i="20943" xml_f="20945" txt_i="14071" txt_f="14073">14</offsets></xref><offsets xml_i="20952" xml_f="21175" txt_i="14073" txt_f="14296">]. Because the ability of the lung microvascular pressure to increase was precluded, the authors interpreted their findings as a result of increased permeability. However, the exact mechanisms involved still remain obscure.</offsets></p><p><offsets xml_i="21182" xml_f="21372" txt_i="14297" txt_f="14487">PKC consists of a set of different isoenzymes: classical (α, β, γ), novel (ε, δ, θ, η), and atypical (ξ, λ), of which only the classical isoforms are sensitive to changes in intracellular Ca</offsets><sup><offsets xml_i="21377" xml_f="21380" txt_i="14487" txt_f="14490">2+ </offsets></sup><offsets xml_i="21386" xml_f="21401" txt_i="14490" txt_f="14505">concentration [</offsets><xref ref-type="bibr" rid="B31"><offsets xml_i="21433" xml_f="21435" txt_i="14505" txt_f="14507">31</offsets></xref><offsets xml_i="21442" xml_f="21509" txt_i="14507" txt_f="14574">]. Recent studies have shown that ET-1 stimulates the release of Ca</offsets><sup><offsets xml_i="21514" xml_f="21517" txt_i="14574" txt_f="14577">2+ </offsets></sup><offsets xml_i="21523" xml_f="21596" txt_i="14577" txt_f="14650">from the endoplasmic reticulum and activates PKC-α in the cell membrane [</offsets><xref ref-type="bibr" rid="B15"><offsets xml_i="21628" xml_f="21630" txt_i="14650" txt_f="14652">15</offsets></xref><offsets xml_i="21637" xml_f="21638" txt_i="14652" txt_f="14653">-</offsets><xref ref-type="bibr" rid="B19"><offsets xml_i="21670" xml_f="21672" txt_i="14653" txt_f="14655">19</offsets></xref><offsets xml_i="21679" xml_f="21796" txt_i="14655" txt_f="14772">]. After being activated, PKC-α has been shown to mediate the disruption of vascular endothelial cadherin junctions [</offsets><xref ref-type="bibr" rid="B32"><offsets xml_i="21828" xml_f="21830" txt_i="14772" txt_f="14774">32</offsets></xref><offsets xml_i="21837" xml_f="21970" txt_i="14774" txt_f="14907">]. Moreover, PKC-α activates myosin light chain kinase, which is involved in endothelial cell gap formation and barrier dysfunction [</offsets><xref ref-type="bibr" rid="B33"><offsets xml_i="22002" xml_f="22004" txt_i="14907" txt_f="14909">33</offsets></xref><offsets xml_i="22011" xml_f="22105" txt_i="14909" txt_f="15003">]. In the lung vasculature, PKC-α-induced disruption might derange the endothelial integrity [</offsets><xref ref-type="bibr" rid="B19"><offsets xml_i="22137" xml_f="22139" txt_i="15003" txt_f="15005">19</offsets></xref><offsets xml_i="22146" xml_f="22527" txt_i="15005" txt_f="15386">]. We therefore speculate that the increase in vascular permeability and the evolution of ALI might be due to ET-1-induced activation of PKC-α in the cell membrane. We believe that blockade of ET-1 receptors, resulting in a combination of reduced microvascular pressure and decreased activation of PKC-α, is one of the main reasons for the amelioration of ALI in the present study.</offsets></p><p><offsets xml_i="22534" xml_f="22656" txt_i="15387" txt_f="15509">It is well established that infusion of LPS stimulates a release of inflammatory mediators such as TNF-α, IL-8, and ET-1 [</offsets><xref ref-type="bibr" rid="B34"><offsets xml_i="22688" xml_f="22690" txt_i="15509" txt_f="15511">34</offsets></xref><offsets xml_i="22697" xml_f="22698" txt_i="15511" txt_f="15512">-</offsets><xref ref-type="bibr" rid="B36"><offsets xml_i="22730" xml_f="22732" txt_i="15512" txt_f="15514">36</offsets></xref><offsets xml_i="22739" xml_f="22841" txt_i="15514" txt_f="15616">]. In contrast, ET-1 stimulates monocytes and macrophages to release TNF-α and IL-8 in its own right [</offsets><xref ref-type="bibr" rid="B37"><offsets xml_i="22873" xml_f="22875" txt_i="15616" txt_f="15618">37</offsets></xref><offsets xml_i="22882" xml_f="22883" txt_i="15618" txt_f="15619">,</offsets><xref ref-type="bibr" rid="B38"><offsets xml_i="22915" xml_f="22917" txt_i="15619" txt_f="15621">38</offsets></xref><offsets xml_i="22924" xml_f="23367" txt_i="15621" txt_f="16064">]. In the present study, enhanced plasma concentrations of TNF-α, IL-8, and ET-1 were found after 4 hours in both endotoxemic groups. However, at the end of the experiments the plasma concentrations of all three mediators were significantly higher in tezosentan-treated animals than in animals given LPS alone. The increases in ET-1 and TNF-α are consistent with a previous investigation employing the endothelin receptor antagonist bosentan [</offsets><xref ref-type="bibr" rid="B39"><offsets xml_i="23399" xml_f="23401" txt_i="16064" txt_f="16066">39</offsets></xref><offsets xml_i="23408" xml_f="23535" txt_i="16066" txt_f="16193">], but in contrast to that short-term study, we exposed sheep to 24 hours of endotoxemia. According to another recent study, ET</offsets><sub><offsets xml_i="23540" xml_f="23542" txt_i="16193" txt_f="16195">B </offsets></sub><offsets xml_i="23548" xml_f="23631" txt_i="16195" txt_f="16278">receptors in the lungs are involved in the clearance of ET-1 from the circulation [</offsets><xref ref-type="bibr" rid="B40"><offsets xml_i="23663" xml_f="23665" txt_i="16278" txt_f="16280">40</offsets></xref><offsets xml_i="23672" xml_f="23818" txt_i="16280" txt_f="16426">]. Consequently, ET-1 receptor blockade prolongs ET-1 half-life in the plasma and reportedly shifts tissue uptake from the lungs to other organs [</offsets><xref ref-type="bibr" rid="B41"><offsets xml_i="23850" xml_f="23852" txt_i="16426" txt_f="16428">41</offsets></xref><offsets xml_i="23859" xml_f="24041" txt_i="16428" txt_f="16610">]. In the present study, tezosentan increased the plasma concentration of ET-1 to an extent that might have enhanced the release of TNF-α and IL-8 from the monocytes and macrophages.</offsets></p><p><offsets xml_i="24048" xml_f="24419" txt_i="16611" txt_f="16982">The present endotoxin-induced lung injury model in sheep is not ideal for elucidating the effects of ET-1 receptor blockade on permeability because microvascular pressure cannot be deliberately changed. Further studies of ET-1 receptor blockade on permeability are therefore required in a more complex experimental setting on intact animals or in isolated perfused lungs.</offsets></p></sec><sec><title><offsets xml_i="24441" xml_f="24451" txt_i="16984" txt_f="16994">Conclusion</offsets></title><p><offsets xml_i="24462" xml_f="25071" txt_i="16995" txt_f="17604">In endotoxemic sheep, ET-1 plasma concentration is significantly correlated with Pmo in the late phase. Moreover, Pmo and extravascular lung water content demonstrate a positive correlation from the first hours of endotoxin infusion. Blockade of ET-1 receptors attenuates ALI by reducing the pulmonary microvascular pressure and most probably also by decreasing permeability secondary to reducing the activation of PKC-α. However, further studies are needed to explain the exact mechanisms behind the decrease in extravascular lung water and the prevention of activation of PKC-α after ET-1 receptor blockade.</offsets></p></sec><sec><title><offsets xml_i="25093" xml_f="25105" txt_i="17606" txt_f="17618">Key messages</offsets></title><p><offsets xml_i="25116" xml_f="25234" txt_i="17619" txt_f="17737">• 	In endotoxemic sheep, extravascular lung water content correlates positively with pulmonary microvascular pressure.</offsets></p><p><offsets xml_i="25241" xml_f="25480" txt_i="17738" txt_f="17977">• 	Non-selective endothelin-1 receptor blockade attenuates ovine endotoxin-induced lung injury by reducing pulmonary microvascular pressure and probably also by decreasing microvascular permeability secondary to reduced activation of PKCα.</offsets></p></sec><sec><title><offsets xml_i="25502" xml_f="25515" txt_i="17979" txt_f="17992">Abbreviations</offsets></title><p><offsets xml_i="25526" xml_f="25760" txt_i="17993" txt_f="18227">ALI = acute lung injury; ET-1 = endothelin-1; EVLWI = extravascular lung water index; IL = interleukin; LPS = lipopolysaccharide; PKC = protein kinase C; Pmo = pulmonary capillary micro-occlusion pressure; TNF = tumor necrosis factor.</offsets></p></sec><sec><title><offsets xml_i="25782" xml_f="25801" txt_i="18229" txt_f="18248">Competing interests</offsets></title><p><offsets xml_i="25812" xml_f="26036" txt_i="18249" txt_f="18473">This study was supported by Helse Nord (Norwegian governmental funds), project number 4001.721.132 and departmental funds of the Departments of Anesthesiology, Physiology and Clinical Chemistry, University of Tromsø, Norway.</offsets></p></sec><sec><title><offsets xml_i="26058" xml_f="26080" txt_i="18475" txt_f="18497">Authors' contributions</offsets></title><p><offsets xml_i="26091" xml_f="26454" txt_i="18498" txt_f="18861">VK participated in the design of the study, analyzed the data, and drafted the manuscript. MK, MS, TA, OCI and KY contributed to the biochemical analysis and participated in the design of the study. LB administered the study, participated in the design of the study and suggested improvements to the manuscript. All authors read and approved the final manuscript.</offsets></p></sec></body><back><ack><sec><title>Acknowledgements</title><p>The authors thank Dr Martine Clozel (Actelion Pharmaceuticals Ltd, Allschwil, Switzerland) for generously giving us tezosentan, and Dr Tormod Brenn PhD and Dr Tom Wilsgaard PhD for review of the statistical methods. A part of this study was presented and awarded a prize at the 17th Annual Congress of the European Society of Intensive Care Medicine, Berlin, Germany, 10 to 13 October, 2004 (<italic>Intensive Care Med </italic>2004, <bold>30 </bold>(Suppl 1):S32, abstract no 504).</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yanagisawa</surname><given-names>M</given-names></name><name><surname>Kurihara</surname><given-names>H</given-names></name><name><surname>Kimura</surname><given-names>S</given-names></name><name><surname>Tomobe</surname><given-names>Y</given-names></name><name><surname>Kobayashi</surname><given-names>M</given-names></name><name><surname>Mitsui</surname><given-names>Y</given-names></name><name><surname>Yazaki</surname><given-names>Y</given-names></name><name><surname>Goto</surname><given-names>K</given-names></name><name><surname>Masaki</surname><given-names>T</given-names></name></person-group><article-title>A novel potent vasoconstrictor peptide produced by vascular endothelial cells</article-title><source>Nature</source><year>1988</year><volume>332</volume><fpage>411</fpage><lpage>415</lpage><pub-id pub-id-type="pmid">2451132</pub-id><pub-id pub-id-type="doi">10.1038/332411a0</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mitaka</surname><given-names>C</given-names></name><name><surname>Hirata</surname><given-names>Y</given-names></name><name><surname>Nagura</surname><given-names>T</given-names></name><name><surname>Tsunoda</surname><given-names>Y</given-names></name><name><surname>Amaha</surname><given-names>K</given-names></name></person-group><article-title>Circulating endothelin-1 concentrations in acute respiratory failure</article-title><source>Chest</source><year>1993</year><volume>104</volume><fpage>476</fpage><lpage>480</lpage><pub-id pub-id-type="pmid">8339637</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Douglas</surname><given-names>SA</given-names></name><name><surname>Beck</surname><given-names>GR</given-names><suffix>Jr</suffix></name><name><surname>Elliott</surname><given-names>JD</given-names></name><name><surname>Ohlstein</surname><given-names>EH</given-names></name></person-group><article-title>Pharmacological evidence for the presence of three distinct functional endothelin receptor subtypes in the rabbit lateral saphenous vein</article-title><source>Br J Pharmacol</source><year>1995</year><volume>114</volume><fpage>1529</fpage><lpage>1540</lpage><pub-id pub-id-type="pmid">7599920</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Nucci</surname><given-names>G</given-names></name><name><surname>Thomas</surname><given-names>R</given-names></name><name><surname>D'Orleans-Juste</surname><given-names>P</given-names></name><name><surname>Antunes</surname><given-names>E</given-names></name><name><surname>Walder</surname><given-names>C</given-names></name><name><surname>Warner</surname><given-names>TD</given-names></name><name><surname>Vane</surname><given-names>JR</given-names></name></person-group><article-title>Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor</article-title><source>Proc Natl Acad Sci USA</source><year>1988</year><volume>85</volume><fpage>9797</fpage><lpage>9800</lpage><pub-id pub-id-type="pmid">3059352</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Masaki</surname><given-names>T</given-names></name></person-group><article-title>Possible role of endothelin in endothelial regulation of vascular tone</article-title><source>Annu Rev Pharmacol Toxicol</source><year>1995</year><volume>35</volume><fpage>235</fpage><lpage>255</lpage><pub-id pub-id-type="pmid">7598493</pub-id><pub-id pub-id-type="doi">10.1146/annurev.pa.35.040195.001315</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pernow</surname><given-names>J</given-names></name><name><surname>Hemsen</surname><given-names>A</given-names></name><name><surname>Lundberg</surname><given-names>JM</given-names></name></person-group><article-title>Increased plasma levels of endothelin-like immunoreactivity during endotoxin administration in the pig</article-title><source>Acta Physiol Scand</source><year>1989</year><volume>137</volume><fpage>317</fpage><lpage>318</lpage><pub-id pub-id-type="pmid">2694766</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Kasai</surname><given-names>K</given-names></name><name><surname>Sekiguchi</surname><given-names>Y</given-names></name><name><surname>Banba</surname><given-names>N</given-names></name><name><surname>Takahashi</surname><given-names>K</given-names></name><name><surname>Emoto</surname><given-names>T</given-names></name><name><surname>Hattori</surname><given-names></given-names></name><name><surname>Shimoda</surname><given-names>S</given-names></name></person-group><article-title>Elevation of plasma endothelin concentrations during endotoxin shock in dogs</article-title><source>Eur J Pharmacol</source><year>1991</year><volume>205</volume><fpage>277</fpage><lpage>282</lpage><pub-id pub-id-type="pmid">1667911</pub-id><pub-id pub-id-type="doi">10.1016/0014-2999(91)90910-I</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mitaka</surname><given-names>C</given-names></name><name><surname>Hirata</surname><given-names>Y</given-names></name><name><surname>Makita</surname><given-names>K</given-names></name><name><surname>Nagura</surname><given-names>T</given-names></name><name><surname>Tsunoda</surname><given-names>Y</given-names></name><name><surname>Amaha</surname><given-names>K</given-names></name></person-group><article-title>Endothelin-1 and atrial natriuretic peptide in septic shock</article-title><source>Am Heart J</source><year>1993</year><volume>126</volume><fpage>466</fpage><lpage>468</lpage><pub-id pub-id-type="pmid">8338025</pub-id><pub-id pub-id-type="doi">10.1016/0002-8703(93)91074-O</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kuklin</surname><given-names>VN</given-names></name><name><surname>Kirov</surname><given-names>MY</given-names></name><name><surname>Evgenov</surname><given-names>OV</given-names></name><name><surname>Sovershaev</surname><given-names>MA</given-names></name><name><surname>Sjoberg</surname><given-names>J</given-names></name><name><surname>Kirova</surname><given-names>SS</given-names></name><name><surname>Bjertnaes</surname><given-names>LJ</given-names></name></person-group><article-title>Novel endothelin receptor antagonist attenuates endotoxin-induced lung injury in sheep</article-title><source>Crit Care Med</source><year>2004</year><volume>32</volume><fpage>766</fpage><lpage>773</lpage><pub-id pub-id-type="pmid">15090960</pub-id><pub-id pub-id-type="doi">10.1097/01.CCM.0000114575.08269.F6</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Henry</surname><given-names>PJ</given-names></name><name><surname>Rigby</surname><given-names>PJ</given-names></name><name><surname>Self</surname><given-names>GJ</given-names></name><name><surname>Preuss</surname><given-names>JM</given-names></name><name><surname>Goldie</surname><given-names>RG</given-names></name></person-group><article-title>Relationship between endothelin-1 binding site densities and constrictor activities in human and animal airway smooth muscle</article-title><source>Br J Pharmacol</source><year>1990</year><volume>100</volume><fpage>786</fpage><lpage>792</lpage><pub-id pub-id-type="pmid">2169940</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McKay</surname><given-names>KO</given-names></name><name><surname>Black</surname><given-names>JL</given-names></name><name><surname>Diment</surname><given-names>LM</given-names></name><name><surname>Armour</surname><given-names>CL</given-names></name></person-group><article-title>Functional and autoradiographic studies of endothelin-1 and endothelin-2 in human bronchi, pulmonary arteries, and airway parasympathetic ganglia</article-title><source>J Cardiovasc Pharmacol</source><year>1991</year><volume>17</volume><fpage>S206</fpage><lpage>S209</lpage><pub-id pub-id-type="pmid">1725334</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Horgan</surname><given-names>MJ</given-names></name><name><surname>Pinheiro</surname><given-names>JM</given-names></name><name><surname>Malik</surname><given-names>AB</given-names></name></person-group><article-title>Mechanism of endothelin-1-induced pulmonary vasoconstriction</article-title><source>Circ Res</source><year>1991</year><volume>69</volume><fpage>157</fpage><lpage>164</lpage><pub-id pub-id-type="pmid">2054931</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Filep</surname><given-names>JG</given-names></name><name><surname>Sirois</surname><given-names>MG</given-names></name><name><surname>Rousseau</surname><given-names>A</given-names></name><name><surname>Fournier</surname><given-names>A</given-names></name><name><surname>Sirois</surname><given-names>P</given-names></name></person-group><article-title>Effects of endothelin-1 on vascular permeability in the conscious rat: interactions with platelet-activating factor</article-title><source>Br J Pharmacol</source><year>1991</year><volume>104</volume><fpage>797</fpage><lpage>804</lpage><pub-id pub-id-type="pmid">1667286</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Helset</surname><given-names>E</given-names></name><name><surname>Kjaeve</surname><given-names>J</given-names></name><name><surname>Hauge</surname><given-names>A</given-names></name></person-group><article-title>Endothelin-1-induced increases in microvascular permeability in isolated, perfused rat lungs requires leukocytes and plasma</article-title><source>Circ Shock</source><year>1993</year><volume>39</volume><fpage>15</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">8481973</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Griendling</surname><given-names>KK</given-names></name><name><surname>Tsuda</surname><given-names>T</given-names></name><name><surname>Alexander</surname><given-names>RW</given-names></name></person-group><article-title>Endothelin stimulates diacylglycerol accumulation and activates protein kinase C in cultured vascular smooth muscle cells</article-title><source>J Biol Chem</source><year>1989</year><volume>264</volume><fpage>8237</fpage><lpage>8240</lpage><pub-id pub-id-type="pmid">2656676</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Danthuluri</surname><given-names>NR</given-names></name><name><surname>Brock</surname><given-names>TA</given-names></name></person-group><article-title>Endothelin receptor-coupling mechanisms in vascular smooth muscle: a role for protein kinase C</article-title><source>J Pharmacol Exp Ther</source><year>1990</year><volume>254</volume><fpage>393</fpage><lpage>399</lpage><pub-id pub-id-type="pmid">2166789</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lynch</surname><given-names>JJ</given-names></name><name><surname>Ferro</surname><given-names>TJ</given-names></name><name><surname>Blumenstock</surname><given-names>FA</given-names></name><name><surname>Brockenauer</surname><given-names>AM</given-names></name><name><surname>Malik</surname><given-names>AB</given-names></name></person-group><article-title>Increased endothelial albumin permeability mediated by protein kinase C activation</article-title><source>J Clin Invest</source><year>1990</year><volume>85</volume><fpage>1991</fpage><lpage>1998</lpage><pub-id pub-id-type="pmid">2347922</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Siflinger-Birnboim</surname><given-names>A</given-names></name><name><surname>Goligorsky</surname><given-names>MS</given-names></name><name><surname>Del Vecchio</surname><given-names>PJ</given-names></name><name><surname>Malik</surname><given-names>AB</given-names></name></person-group><article-title>Activation of protein kinase C pathway contributes to hydrogen peroxide-induced increase in endothelial permeability</article-title><source>Lab Invest</source><year>1992</year><volume>67</volume><fpage>24</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">1378104</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Siflinger-Birnboim</surname><given-names>A</given-names></name><name><surname>Johnson</surname><given-names>A</given-names></name></person-group><article-title>Protein kinase C modulates pulmonary endothelial permeability: a paradigm for acute lung injury</article-title><source>Am J Physiol Lung Cell Mol Physiol</source><year>2003</year><volume>284</volume><fpage>L435</fpage><lpage>L451</lpage><pub-id pub-id-type="pmid">12573983</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bjertnaes</surname><given-names>LJ</given-names></name><name><surname>Koizumi</surname><given-names>T</given-names></name><name><surname>Newman</surname><given-names>JH</given-names></name></person-group><article-title>Inhaled nitric oxide reduces lung fluid filtration after endotoxin in awake sheep</article-title><source>Am J Respir Crit Care Med</source><year>1998</year><volume>158</volume><fpage>1416</fpage><lpage>1423</lpage><pub-id pub-id-type="pmid">9817688</pub-id></citation></ref><ref id="B21"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Kleinbaum</surname><given-names>DG</given-names></name><name><surname>Kupper</surname><given-names>LL</given-names></name><name><surname>Muller</surname><given-names>KE</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Kleinbaum DG</surname></name></person-group><article-title>Method II: using a single regression equation to compare two straight lines</article-title><source>Applied Regression Analysis and Multivariable Methods</source><year>1998</year><edition>3</edition><publisher-name>Pacific Grove, California: Duxbury Press</publisher-name><fpage>327</fpage><lpage>328</lpage></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Block</surname><given-names>ER</given-names></name></person-group><article-title>Pulmonary endothelial cell pathology: implications for acute lung injury</article-title><source>Am J Med Sci</source><year>1992</year><volume>304</volume><fpage>136</fpage><lpage>144</lpage><pub-id pub-id-type="pmid">1503113</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Traber</surname><given-names>DL</given-names></name><name><surname>Adair</surname><given-names>TH</given-names></name><name><surname>Adams</surname><given-names>T</given-names><suffix>Jr</suffix></name></person-group><article-title>Hemodynamic consequences of endotoxemia in sheep</article-title><source>Circ Shock</source><year>1981</year><volume>8</volume><fpage>551</fpage><lpage>561</lpage><pub-id pub-id-type="pmid">7285288</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kutzsche</surname><given-names>S</given-names></name><name><surname>Lyberg</surname><given-names>T</given-names></name><name><surname>Bjertnaes</surname><given-names>LJ</given-names></name></person-group><article-title>Effects of adenosine on extravascular lung water content in endotoxemic pigs</article-title><source>Crit Care Med</source><year>2001</year><volume>29</volume><fpage>2371</fpage><lpage>3276</lpage><pub-id pub-id-type="pmid">11801842</pub-id><pub-id pub-id-type="doi">10.1097/00003246-200112000-00021</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Albertini</surname><given-names>M</given-names></name><name><surname>Ciminaghi</surname><given-names>B</given-names></name><name><surname>Mazzola</surname><given-names>S</given-names></name><name><surname>Clement</surname><given-names>MG</given-names></name></person-group><article-title>Improvement of respiratory function by bosentan during endotoxic shock in the pig</article-title><source>Prostaglandins Leukot Essent Fatty Acids</source><year>2001</year><volume>65</volume><fpage>103</fpage><lpage>108</lpage><pub-id pub-id-type="pmid">11545627</pub-id><pub-id pub-id-type="doi">10.1054/plef.2001.0296</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Henry</surname><given-names>C</given-names></name><name><surname>Ogletree</surname><given-names>M</given-names></name><name><surname>Brigham</surname><given-names>K</given-names></name><name><surname>Hammon</surname><given-names>JW</given-names><suffix>Jr</suffix></name></person-group><article-title>Attenuation of the pulmonary vascular response to endotoxin by a thromboxane synthesis inhibitor (UK-38485) in unanesthetized sheep</article-title><source>J Surg Res</source><year>1991</year><volume>50</volume><fpage>77</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">1987435</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Morel</surname><given-names>DR</given-names></name><name><surname>Pittet</surname><given-names>JF</given-names></name><name><surname>Gunning</surname><given-names>K</given-names></name><name><surname>Hemsen</surname><given-names>A</given-names></name><name><surname>Lacroix</surname><given-names>JS</given-names></name><name><surname>Lundberg</surname><given-names>JM</given-names></name></person-group><article-title>Time course of plasma and pulmonary lymph endothelin-like immunoreactivity during sustained endotoxaemia in chronically instrumented sheep</article-title><source>Clin Sci</source><year>1991</year><volume>81</volume><fpage>357</fpage><lpage>365</lpage><pub-id pub-id-type="pmid">1655337</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weitzberg</surname><given-names>E</given-names></name></person-group><article-title>Circulatory responses to endothelin-1 and nitric oxide with special reference to endotoxin shock and nitric oxide inhalation</article-title><source>Acta Physiol Scand Suppl</source><year>1993</year><volume>611</volume><fpage>1</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">8379340</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schmeck</surname><given-names>J</given-names></name><name><surname>Heller</surname><given-names>A</given-names></name><name><surname>Groschler</surname><given-names>A</given-names></name><name><surname>Recker</surname><given-names>A</given-names></name><name><surname>Neuhof</surname><given-names>H</given-names></name><name><surname>Urbaschek</surname><given-names>R</given-names></name><name><surname>Koch</surname><given-names>T</given-names></name></person-group><article-title>Impact of endothelin-1 in endotoxin-induced pulmonary vascular reactions</article-title><source>Crit Care Med</source><year>2000</year><volume>28</volume><fpage>2851</fpage><lpage>2857</lpage><pub-id pub-id-type="pmid">10966261</pub-id><pub-id pub-id-type="doi">10.1097/00003246-200008000-00028</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rossi</surname><given-names>P</given-names></name><name><surname>Wanecek</surname><given-names>M</given-names></name><name><surname>Konrad</surname><given-names>D</given-names></name><name><surname>Oldner</surname><given-names>A</given-names></name></person-group><article-title>Tezosentan counteracts endotoxin-induced pulmonary edema and improves gas exchange</article-title><source>Shock</source><year>2004</year><volume>21</volume><fpage>543</fpage><lpage>548</lpage><pub-id pub-id-type="pmid">15167683</pub-id><pub-id pub-id-type="doi">10.1097/01.shk.0000126147.76311.18</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mellor</surname><given-names>H</given-names></name><name><surname>Parker</surname><given-names>PJ</given-names></name></person-group><article-title>The extended protein kinase C superfamily</article-title><source>Biochem J</source><year>1998</year><volume>332</volume><fpage>281</fpage><lpage>292</lpage><pub-id pub-id-type="pmid">9601053</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sandoval</surname><given-names>R</given-names></name><name><surname>Malik</surname><given-names>AB</given-names></name><name><surname>Minshall</surname><given-names>RD</given-names></name><name><surname>Kouklis</surname><given-names>P</given-names></name><name><surname>Ellis</surname><given-names>CA</given-names></name><name><surname>Tiruppathi</surname><given-names>C</given-names></name></person-group><article-title>Ca<sup>2+ </sup>signalling and PKCα activate increased endothelial permeability by disassembly of VE-cadherin junctions</article-title><source>J Physiol</source><year>2001</year><volume>533</volume><fpage>433</fpage><lpage>445</lpage><pub-id pub-id-type="pmid">11389203</pub-id><pub-id pub-id-type="doi">10.1111/j.1469-7793.2001.0433a.x</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Garcia</surname><given-names>JG</given-names></name><name><surname>Davis</surname><given-names>HW</given-names></name><name><surname>Patterson</surname><given-names>CE</given-names></name></person-group><article-title>Regulation of endothelial cell gap formation and barrier dysfunction: role of myosin light chain phosphorylation</article-title><source>J Cell Physiol</source><year>1995</year><volume>163</volume><fpage>510</fpage><lpage>522</lpage><pub-id pub-id-type="pmid">7775594</pub-id><pub-id pub-id-type="doi">10.1002/jcp.1041630311</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sugiura</surname><given-names>M</given-names></name><name><surname>Inagami</surname><given-names>T</given-names></name><name><surname>Kon</surname><given-names>V</given-names></name></person-group><article-title>Endotoxin stimulates endothelin-release in vivo and in vitro as determined by radioimmunoassay</article-title><source>Biochem Biophys Res Commun</source><year>1989</year><volume>161</volume><fpage>1220</fpage><lpage>1227</lpage><pub-id pub-id-type="pmid">2662974</pub-id><pub-id pub-id-type="doi">10.1016/0006-291X(89)91372-7</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beutler</surname><given-names>B</given-names></name><name><surname>Cerami</surname><given-names>A</given-names></name></person-group><article-title>The biology of cachectin/TNF – a primary mediator of the host response</article-title><source>Annu Rev Immunol</source><year>1989</year><volume>7</volume><fpage>625</fpage><lpage>655</lpage><pub-id pub-id-type="pmid">2540776</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mathison</surname><given-names>JC</given-names></name><name><surname>Wolfson</surname><given-names>E</given-names></name><name><surname>Ulevitch</surname><given-names>RJ</given-names></name></person-group><article-title>Participation of tumor necrosis factor in the mediation of gram negative bacterial lipopolysaccharide-induced injury in rabbits</article-title><source>J Clin Invest</source><year>1988</year><volume>81</volume><fpage>1925</fpage><lpage>1237</lpage><pub-id pub-id-type="pmid">3384955</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Helset</surname><given-names>E</given-names></name><name><surname>Sildnes</surname><given-names>T</given-names></name><name><surname>Seljelid</surname><given-names>R</given-names></name><name><surname>Konopski</surname><given-names>S</given-names></name></person-group><article-title>Endothelin-1 stimulates human monocytes in vitro to release TNF-1α, IL-1β and IL-6</article-title><source>Mediators Inflamm</source><year>1993</year><volume>2</volume><fpage>417</fpage><lpage>422</lpage></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Helset</surname><given-names>E</given-names></name><name><surname>Sildnes</surname><given-names>T</given-names></name><name><surname>Konopski</surname><given-names>S</given-names></name></person-group><article-title>Endothelin-1 stimulates monocytes in vitro to release chemotactic activity identified as interleukin-8 and monocyte chemotactic protein-1</article-title><source>Mediators Inflamm</source><year>1994</year><volume>3</volume><fpage>155</fpage><lpage>160</lpage></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wanecek</surname><given-names>M</given-names></name><name><surname>Oldner</surname><given-names>A</given-names></name><name><surname>Rudehill</surname><given-names>A</given-names></name><name><surname>Sollevi</surname><given-names>A</given-names></name><name><surname>Alving</surname><given-names>K</given-names></name><name><surname>Weitzberg</surname><given-names>E</given-names></name></person-group><article-title>Cardiopulmonary dysfunction during porcine endotoxin shock is effectively counteracted by the endothelin receptor antagonist bosentan</article-title><source>Shock</source><year>1997</year><volume>7</volume><fpage>364</fpage><lpage>370</lpage><pub-id pub-id-type="pmid">9165672</pub-id></citation></ref><ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shiba</surname><given-names>R</given-names></name><name><surname>Yanagisawa</surname><given-names>M</given-names></name><name><surname>Miyauchi</surname><given-names>T</given-names></name><name><surname>Ishii</surname><given-names>Y</given-names></name><name><surname>Kimura</surname><given-names>S</given-names></name><name><surname>Uchiyama</surname><given-names>Y</given-names></name><name><surname>Masaki</surname><given-names>T</given-names></name><name><surname>Goto</surname><given-names>K</given-names></name></person-group><article-title>Elimination of intravenously injected endothelin-1 from the circulation of the rat</article-title><source>J Cardiovasc Pharmacol</source><year>1989</year><volume>13</volume><fpage>S98</fpage><lpage>S101</lpage><pub-id pub-id-type="pmid">2473338</pub-id></citation></ref><ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Burkhardt</surname><given-names>M</given-names></name><name><surname>Barton</surname><given-names>M</given-names></name><name><surname>Shaw</surname><given-names>SG</given-names></name></person-group><article-title>Receptor- and non-receptor-mediated clearance of big-endothelin and endothelin-1: differential effects of acute and chronic ETA receptor blockade</article-title><source>J Hypertens</source><year>2000</year><volume>18</volume><fpage>273</fpage><lpage>279</lpage><pub-id pub-id-type="pmid">10726713</pub-id><pub-id pub-id-type="doi">10.1097/00004872-200018030-00006</pub-id></citation></ref></ref-list><sec sec-type="display-objects"><title>Figures and Tables</title><fig position="float" id="F1"><label>Figure 1</label><caption><p>Relationship between plasma concentration of endothelin-1 (ET-1) and pulmonary micro-occlusion pressure (Pmo) in sheep. <bold>(a) </bold>From 0 to 12 hours of LPS infusion (<italic>r </italic>= -0.51, <italic>P </italic>= 0.12, <italic>n </italic>= 10); <bold>(b) </bold>from 12 to 24 hours of LPS infusion (<italic>r </italic>= 0.75, <italic>P </italic>&lt; 0.01, <italic>n </italic>= 9).</p></caption><graphic xlink:href="cc3497-1"></graphic></fig><fig position="float" id="F2"><label>Figure 2</label><caption><p>Relationship between extravascular lung water index (EVLWI) and pulmonary micro-occlusion pressure (Pmo) in endotoxemic sheep. LPS alone (r = 0.73, P &lt; 0.01, n = 42). LPS with tezosentan (r = 0.67, P &lt; 0.0001, n = 42).</p></caption><graphic xlink:href="cc3497-2"></graphic></fig><fig position="float" id="F3"><label>Figure 3</label><caption><p>Protein kinase Cα (PKC-α) in sheep lung tissue homogenates detected by Western blotting. <bold>(a) </bold>In the cytosolic fraction; <bold>(b) </bold>in the membrane fraction. Results are means ± SEM. Groups were as follows: sham-operated group (<italic>n </italic>= 3); lipopolysaccharide group (LPS; <italic>n </italic>= 4); LPS plus tezosentan group (<italic>n </italic>= 4). <sup>†</sup><italic>P </italic>&lt; 0.05 between sham-operated and LPS groups; <sup>‡</sup><italic>P </italic>&lt; 0.05 between LPS and LPS plus tezosentan groups.</p></caption><graphic xlink:href="cc3497-3"></graphic></fig><fig position="float" id="F4"><label>Figure 4</label><caption><p>Plasma concentration of endothelin-1 (ET-1), tumor necrosis factor-α (TNF-α) and interleukin-8 (IL-8). Results are means ± SEM. Groups were as follows: sham-operated group (<italic>n </italic>= 3); lipopolysaccharide group (LPS; <italic>n </italic>= 7); LPS plus tezosentan group (<italic>n </italic>= 7). ND, not detectable. <sup>†</sup><italic>P </italic>&lt; 0.05 between sham-operated and LPS groups; <sup>‡</sup><italic>P </italic>&lt; 0.05 between LPS and LPS plus tezosentan groups; *<italic>P </italic>&lt; 0.05 between sham-operated and LPS plus tezosentan groups; <sup>&amp;</sup><italic>P </italic>&lt; 0.05 from <italic>t </italic>= 0 hours in the LPS group; <sup>§</sup><italic>P </italic>&lt; 0.05 from <italic>t </italic>= 0 hours in the tezosentan group.</p></caption><graphic xlink:href="cc3497-4"></graphic></fig></sec></back></article>